There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .
Use of the Romanian product Silimarina in the treatment of chronic liver diseases.
The Romanian product Silimarina ( synonym Legalon ) was administered in a r and omized double-blind trial , to a group of 180 patients with chronic persistent hepatitis ( CPH ) , chronic active hepatitis ( CAH ) and hepatic cirrhosis ( HC ) . The trial lasted for 40 days . The results showed favourable effects similar with those obtained with other preparations produced by foreign drug industries . The Romanian product proved to have no toxic effect . The authors discuss the present possibilities of estimating the evolution of chronic liver disease
There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .